Interactions with other drugs acting on the serotonin system or impairing the metabolism of serotonin may increase the risk of serotonin syndrome or neuroleptic malignant syndrome (NMS)-like reaction. Such reactions have been observed with SNRIs and SSRIs alone, but particularly with concurrent use of triptans, MAO inhibitors, antipsychotics, or other dopamine antagonists. The prescribing information states that<unk>  should "not be used in combination with an MAOI (including linezolid, an antibiotic which is a reversible non-selective MAOI), or within 14 days of discontinuing treatment with an MAOI", and should not be used in combination with pimozide, thioridazine, tryptophan, or warfarin.<unk>  interacts with the following cytochrome P450 enzymes: * CYP2D6 for which it is both a substrate and a potent inhibitor. * CYP2B6 (strong) inhibitor. * CYP3A4 (weak) inhibitor. * CYP1A2 (weak) inhibitor. * CYP2C9 (weak) inhibitor. * CYP2C19 (weak) inhibitor.<unk>  has been shown to be an inhibitor of G protein-coupled receptor kinase 2 (GRK2).
Paroxetine
Atomoxetine
Dapoxetine
Citalopram
Reboxetine
Escitalopram
Duloxetine
Fluoxetine